Correlation between metallothionein (MT) expression and selected prognostic factors in ductal breast cancers

Folia Histochemica et Cytobiologica

Volumn 48, Issue 2, 2010, Pages 242-248

  Gomulkiewicz, Agnieszka ^a   Podhorska Okolow, Marzena ^a   Szulc, Rafal ^a   Smorag, Zbigniew ^c   Wojnar, Andrzej ^c   Zabel, Maciej ^a,b   Dziegiel, Piotr ^a,b,c  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^c Wroclaw   (Poland)

Author keywords

Breast cancer; Metallothionein

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; METALLOTHIONEIN I; METALLOTHIONEIN II; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; CANCER GRADING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; QUANTITATIVE STUDY; TISSUE DIFFERENTIATION;

EID: 77957223609     PISSN: 02398508     EISSN: None     Source Type: Journal    
DOI: 10.2478/v10042-010-0011-5     Document Type: Article

References (50)

1. Coyle P, Philcox JC, Carey LC, Rofe AM. Metallothionein: the multipurpose protein. Cell Mol Sci. 2002;59:627-647.
2. Vasak M. Advances in metallothionein structure and functions. J Trace Elem Med Biol. 2005;19:13-17.
3. Theocharis SE, Margeli AP, Klijanienko JT, Kouraklis GP. Metallothionein expression in human neoplasia. Histopathology. 2004;45:103-118.
4. Miles AT, Hawksworth GM, Beattie JH, Rodilla V. Induction, regulation, degradation and biological significance of mammalian metallothioneins. Crit Rev Biochem Mol Biol. 2000; 35:35-70.
5. Ghoshal K, Jacob ST. Regulation of metallothionein gene expression. Prog Nucleic Acid Res Mol Biol. 2001;66:357-384.
6. Saydam N, Adams TK, Steiner F, Schaffner W, Freedman JH. Regulation of metallothionein transcription by the metalresponsive transcription factor MTF-1: identification of signal transduction cascades that control metal inducible transcription. J Biol Chem. 2002;277:20438-20445.
7. Haq F, Mahoney M, Koropatnick J. Signaling events for metallothionein induction. Mutat Res. 2003;533:211-226.
8. Romero-Isart N, Vasak M. Advances in the structure and chemistry of metallothioneins. J Inorg Biochem. 2002;88: 388-396.
9. Theocharis SE, Margeli AP, Koutselinis A. Metallothionein: a multifunctional protein from toxicity to cancer. Int J Biol Markers. 2003;18:162-169.
10. Cherian MG, Jayasurya A, Bay BH. Metallothioneins in human tumors and potential roles in carcinogenesis. Mutat Res. 2003;533:201-209.
11. Dziegiel P. Expression of metallothionein in tumor cells. Pol J Pathol. 2004;55:3-12.
12. Shimoda R, Achanzar WE, Qu W. Metallothionein is a potential negative regulator of apoptosis. Toxicol Sci. 2003;73:294-300.
13. Bay BH, Jin R, Huang J, Tan PH. Metallothionein as a prognostic biomarker in breast cancer. Exp Biol Med. 2006;231:1516-1521.
14. Cherian MG, Apostolova MD. Nuclear localization of metallothionein during cell proliferation and differentiation. Cell Mol Biol. 2000;46:347-356.
15. Jin R, Huang J, Tan PH, Bay BH. Clinicopathological significance of metallothioneins in breast cancer. Pathol Oncol Res. 2004;10:74-79.
16. Meplan C, Richard MJ, Hainaut P. Metalloregulation of the tumor suppressor protein p53: zinc mediates the renaturation of p53 after exposure to metal chelators in vitro and in intact cells. Oncogene. 2000;19:5227-5236.
17. Fan LZ, Cherian MG. Potential role of p53 on metallothionein induction in human epithelial breast cancer cells. Br J Cancer. 2002;87:1019-1026.
18. Ostrakhovitch EA, Olsson PE, Jiang S, Cherian MG. Interaction of metallothionein with tumor suppressor p53 protein. FEBS Lett. 2006;580:1235-1238.
19. Ostrakhovitch EA, Olsson PE, von Hofsten J, Cherian MG. P53 mediated regulation of metallothionein transcription in breast cancer cells. J Cell Biochem. 2007;102:1571-1583.
20. Cardoso SV, Silveira-Junior JB, De Carvalho Machado V, De-Paula AM, Loyla AM, De Aguiar MC. Expression of metallothionein and p53 antigens are correlated in oral squamous cell carcinoma. Anticancer Res. 2009;27:1189-1194.
21. Abdel-Mageed AB, Agrawal KC. Activation of nuclear factor kappa B: potential role in metallothionein-mediated mitogenic response. Cancer Res. 1998;58:2335-2338.
22. Kim CH, Kim JH, Lee J, Ahn YS. Zinc-induced NF-B inhibition can be modulated by changes in the intracellular metollothionein level. Toxicol Appl Pharmacol. 2003;190:189-196.
23. Rosen PP. Invasive duct carcinoma: assessment of prognosis, morphologic prognostic markers and tumor growth rate. In: Pine JW, McGough J, ed. Rosen's Breast Pathology. New York: Lippincott Wiliams and Wilkins, a Wolters Kluwer business; 2009:358-404.
24. Remmele W, Stenger HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection in breast cancer tissue. Pathologe. 1987;8:138-140.
25. Mueller-Holzner E, Fink V, Frede T, Marth C. Immunohistochemical determination of HER-2 expression in breast ancer from core biopsy specimen: a reliable predictor of HER-2 status of the whole tumor. Breast Cancer Res Treat. 2001;69:13-19.
26. Joseph MG, Banerjee D, Kocha W, Feld R, Stitt LW, Cherian MG. Metallothionein expression in patients with small cell carcinoma of the lung. Correlation with other molecular markers and clinical outcome. Cancer. 2001;92:836-842.
27. Hengstler JG, Pilch H, Schmidt M et al. Metallothionein expression in ovarian cancer in relation to histopathological parameters and molecular markers of prognosis. Int. J. Cancer. 2001;95:121-127.
28. Saga Y, Hashimoto H, Yachiku S, Tokumitsu M, Kanenko S. Immunohistochemical expression of metallothionein in human bladder cancer: correlation with histopathological parameters and patient survival. J Urol. 2002;168:2227-2231.
29. Dziegiel P, Forgacz J, Suder E, Surowiak P, Kornafel J, Zabel M. Prognostic significance of metallothionein expression in correlation with Ki-67 expression in adenocarcinoma of large intestine. Histol Histopathol. 2003;18:401-407.
30. Mitropoulos D, Kyroudi-Voulgari A, Theocharis S et al. Prognostic significance of metalothionein expression in renal cell carcinoma. World J Surg Oncol. 2005;3:1-7.
31. Hishikawa Y, Kohno H, Ueda S et al. Expression of metallothionein in colorectal cancers and synchronous liver metastases. Oncology. 2001;61:162-167.
32. Hishikawa Y, Koji T, Dhar DK, Kinugasa S, Yamaguchi M, Nagasue N. Metallothionein expression correlates with metastatic and proliferative potential in squamous cell carcinoma of the esophagus. Br J Cancer. 1999;81:712-720.
33. Sutoh I, Koho H, Nakashima Y et al. Concurrent expression of metallothionein, glutathione S transferase π end P-lycoprotein in colorectal cancer. Dis Colon Rectum. 2000;43:221-232.
34. Cardoso SV, Barbosa HM, Candellori IM. Prognostic impact of metallothionein on oral squamous carcinoma. Virchows Arch. 2002;441:174-178.
35. Surowiak P, Materna V, Maciejczyk A et al. Nuclear metallothionein expression correlates with cisplatin resistance ofovarian cancer cells and poor clinical outcome. Virchows Arch. 2007;450:279-285.
36. Yap X, Tan HY, Huang J et al. Over-expression of metallothionein predicts chemoresistance in breast cancer. J Pathol. 2009;217:563-570.
37. Bier B, Douglas-Jones A, Totsch MI et al. Immunohistochemical demonstration of metallothionein in normal human breast and benign and malignant breast lesions. Breast Cancer Res Treat. 1994;30:213-221.
38. Nagel WW, Vallee BL. Cell cycle regulation of metallothionein in human colonic cancer cells. Proc Natl Acad Sci. 1995;92:579-583.
39. Abdel-Mageed AB, Agrawal KC. Antisense down-regulation of metallothionein induces growth arrest and apoptosis in human breast carcinoma cells. Cancer Gene Ther. 1997;4: 199-207.
40. Dziegiel P, Zabel M. Role of immunohistochemical expression of Ki-67 in adenocarcinoma of large intestine. In: Hayat MA, ed. Handbook of Immunohistochemistry and In Situ Hybrydization of Human Carcinomas. Vol 4. Elsevier; 2006:127-134.
41. Jin R, Chow VTK, Tan PH, Dheen ST, Duan W, Bay BH. Metallothionein 2A expression is associated with cell proliferation in breast cancer. Carcinogenesis. 2002;23:81-86.
42. Jayasurya A, Bay BH, Yap WM, Tan NG, Tan BKH. Proliferative potential in nasopharyngeal carcinoma: correlations with metallothionein expression and tissue zinc levels. Carcinogenesis. 2000;21:1809-1812.
43. Dziegiel P, Salwa-Zurawska W, Zurawski J, Wojnar A, Zabel M. Prognostic significance of augmented metallothionein (MT) expression correlated with Ki-67 antigen expression in selected soft tissue sarcomas. Histol Histopathol. 2005;20:83-89.
44. Jin R, Bay BH, Chow VTK, Tan PH. Metallothionein 1F mRNA expression correlates with histological grade in breast carcinoma. Breast Cancer Res Treat. 2001;66:265-272.
45. Gallicchio LM, Flaws JA, Fowler BA, Ioffe OB. Metallothionein expression in invasive and in situ breast carcinomas. Cancer Detect Prev. 2005;29:332-337.
46. Ross JS, Fletcher JA. HER-2/neu (c-erb-B2) gene and protein in breast cancer. Am J Clin Pathol. 1999;112:53-67.
47. Jensen EV, Cheng G, Palinmieri C et al. Estrogen receptors and proliferation markers in primary and recurrent breast cancer. Proc Natl Acad Sci. 2001;98:15197-15202.
48. Ioachim E, Kamina S, Demou A, Kontostolis M, Lolis D, Agnantis N. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation. Anticancer Res. 1999;19:2133-2140.
49. Ioachim E, Tsanou E, Briasoulis E et al. Clinicopathological study of the expression of hsp27, pS2, cathepsin D and etallothionein in primary invasive breast cancer. Breast. 2003; 12:111-119.
50. Ioachim E, Kitsiou E, Carassavoglou C, Stefankaki S, Agnantis NJ. Immunohistochemical localization of metallothionein in endometrial lesions. J Pathol. 2000;191:269-273.